NASDAQ:SRDX Surmodics (SRDX) Stock Price, News & Analysis $41.97 -0.01 (-0.02%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$41.89▼$41.9750-Day Range$25.69▼$42.1052-Week Range$25.17▼$42.36Volume387,300 shsAverage Volume164,718 shsMarket Capitalization$598.49 millionP/E Ratio44.18Dividend YieldN/APrice Target$50.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Surmodics alerts: Email Address Surmodics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside19.1% Upside$50.00 Price TargetShort InterestHealthy4.43% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews Sentiment0.38Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector252nd out of 879 stocksSurgical & Medical Instruments Industry31st out of 95 stocks 2.0 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSurmodics has only been the subject of 4 research reports in the past 90 days.Read more about Surmodics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.43% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently increased by 18.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 1.9 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Surmodics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SRDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surmodics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to grow in the coming year, from ($0.51) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is 44.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is 44.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.85.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Surmodics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About Surmodics Stock (NASDAQ:SRDX)Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More SRDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRDX Stock News HeadlinesJuly 3, 2024 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDXJuly 3, 2024 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Now Covered by Analysts at StockNews.comJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 30, 2024 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Sees Strong Trading VolumeJune 10, 2024 | businesswire.comSurmodics Awarded Thrombectomy Products Agreement with Premier, Inc.May 29, 2024 | prnewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.May 29, 2024 | marketwatch.comSurmodics Shares Up in Premarket on $627M Go-Private Deal With GTCRMay 29, 2024 | msn.comHeico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On WednesdayJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 29, 2024 | markets.businessinsider.comGTCR To Acquire Surmodics - Quick FactsMay 29, 2024 | tmcnet.comSRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to ShareholdersMay 29, 2024 | msn.comSurmodics jumps 18% on acquisition by GTCRMay 29, 2024 | benzinga.comWhy Is Medical Coating Specialist Surmodics Trading Higher On Wednesday?May 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public ShareholdersMay 29, 2024 | businesswire.comSurmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 MillionMay 21, 2024 | finance.yahoo.comSurmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 96% Above Its Share PriceMay 4, 2024 | finance.yahoo.comSurmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)See More Headlines Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/07/2024Next Earnings (Estimated)8/07/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees376Year Founded1979Price Target and Rating Average Stock Price Target$50.00 High Stock Price Target$71.00 Low Stock Price Target$43.00 Potential Upside/Downside+19.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.95 Trailing P/E Ratio44.18 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,540,000.00 Net Margins9.44% Pretax Margin12.10% Return on Equity13.30% Return on Assets8.63% Debt Debt-to-Equity Ratio0.24 Current Ratio4.39 Quick Ratio3.59 Sales & Book Value Annual Sales$132.58 million Price / Sales4.51 Cash Flow$0.78 per share Price / Cash Flow53.52 Book Value$8.48 per share Price / Book4.95Miscellaneous Outstanding Shares14,260,000Free Float12,991,000Market Cap$598.49 million OptionableOptionable Beta1.18 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gary R. Maharaj (Age 61)CEO, President & Director Comp: $1.33MMr. Timothy J. Arens (Age 57)Senior VP of Finance & Information Technology and CFO Comp: $645.3kMr. Gordon S. Weber (Age 61)Senior VP of Legal, General Counsel & Secretary Comp: $602.84kMr. Charles W. Olson (Age 60)Senior VP & President of Medical Device Coatings Comp: $618.47kMs. Teryl L. W. Sides (Age 54)Senior VP & President of Vascular Interventions Comp: $744.38kMr. John D. Manders (Age 43)Corporate Controller, VP of Finance & Principal Accounting Officer Mr. Joseph J. Stich (Age 59)Senior VP of Human Resources & President of In Vitro Diagnostics Comp: $570.92kMore ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKIntersect ENTNASDAQ:XENTAntares PharmaNASDAQ:ATRSCytosorbentsNASDAQ:CTSOVapothermNYSE:VAPOView All CompetitorsInstitutional OwnershipKennedy Capital Management LLCSold 938 shares on 5/16/2024Ownership: 0.971%Jacobs Levy Equity Management Inc.Sold 6,212 shares on 5/16/2024Ownership: 0.854%California State Teachers Retirement SystemSold 882 shares on 5/16/2024Ownership: 0.010%Lazard Asset Management LLCBought 673 shares on 5/15/2024Ownership: 0.040%Public Employees Retirement Association of ColoradoSold 333 shares on 5/15/2024Ownership: 0.013%View All Institutional Transactions SRDX Stock Analysis - Frequently Asked Questions How have SRDX shares performed this year? Surmodics' stock was trading at $36.35 at the beginning of the year. Since then, SRDX shares have increased by 15.5% and is now trading at $41.97. View the best growth stocks for 2024 here. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) posted its earnings results on Wednesday, May, 1st. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.43. The firm had revenue of $31.96 million for the quarter, compared to the consensus estimate of $28.79 million. Surmodics had a net margin of 9.44% and a trailing twelve-month return on equity of 13.30%. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM) and uniQure (QURE). This page (NASDAQ:SRDX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRDX Stock Alerts